期刊文献+

腺病毒介导p16基因的表达及其对肺癌细胞的周期阻滞作用

p16 Gene Expression Mediated by Adenovirus and Its Effect on Cell Cycle Arrest
下载PDF
导出
摘要 目的:以增殖缺陷型腺病毒载体介导p16基因感染人肺腺癌细胞系,观察并鉴定该基因在细胞中的表达及其对细 胞周期和细胞凋亡的影响。方法:采用293细胞内同源重组的方法,制备重组腺病毒Ad5-p16,感染肺腺癌细胞SPC-A1;免疫 组化方法鉴定P16蛋白的表达;台盼蓝染色计数活细胞数,绘制细胞生长曲线;流式细胞术(FCM)分析细胞周期及细胞凋亡 的变化。结果:以MOI=10的重组增殖缺陷型腺病毒Ad5-p16感染SPC-A1细胞48 h后,P16蛋白表达的阳性细胞比率为 71%;以MOI=100感染SPC-A1细胞后第2天,细胞开始出现生长抑制及细胞病变;FCM分析发现细胞在感染腺病毒后出现 细胞周期阻滞和细胞凋亡。结论:以腺病毒为载体介导p16基因在SPC-A1细胞内表达,可发挥抑制细胞生长、诱发细胞凋亡 的作用。本项基因治疗策略以直接调控细胞周期的抑癌基因为靶向治疗基因,为肺癌基因治疗提供了可靠的理论依据。 Objective: To investigate the p16 gene expression in lung cancer cell line introduced by adenovirus, and to observe the effect of p16 gene on cell cycle arrest. Methods: The replication-deficient adenovirus Ad5-pl6 was homolo gously recombined in 293 cells and used to infect the lung cancer cell line SPC-A1. The expression of P16 protein was i dentified by immunohistochemistry. Trypan blue staining was used to count the alive cells and to draw a cellular growth curve. The changes of cell cycle and apoptosis were analyzed by flow cytometry (FCM). Results: After 48 hours since the SPC-A1 cells were infected by the replication-deficient adenovirus Ad5-p16 at MOI = 10, the positive rate of the cells for P16 expression was 71%. The cellular growth inhibition and cytopathic effects were present when the cells were infected with Ad5-p16 at MOI = 100. The cell cycle arrest and the cell apoptosis were found by FCM. Conclusion: The expression of p16 gene in SPC-A1 lung cancer cells induced by the replication-deficient adenovirus may result in the inhibition of cell growth and the introduction of cell apoptosis. The strategy targeted to the tumor suppressor gene that regulates the cell cycle directly, obtained satisfactory results, and provided a reliable theory for lung cancer gene therapy.
出处 《中国肿瘤生物治疗杂志》 CAS CSCD 2004年第4期267-271,共5页 Chinese Journal of Cancer Biotherapy
基金 国家十五科技攻关计划课题(No.2001BA703811)
关键词 腺病毒 抑癌基因 肺癌 基因治疗 adenovirus tumor suppressor gene lung cancer gene therapy
  • 相关文献

参考文献9

  • 1Santos LL, Amaro T, Pereira SA, et al. Expression of cell-cycle regulatory proteins and their prognostic value in superficial lowgrade urothelial cell carcinoma of the bladder [ J]. Eur J Surg Oncol, 2003, 29(1): 74-80.
  • 2Tamm I, Schumacher A, Karawajew L, et al. Adenovirus-mediated gene transfer of P16INK4/CDKN2 into bax-negative colon cancer cells induces apoptosis and tumor regression in vivo [ J ].Cancer Gene Ther, 2002, 9(8): 641-650.
  • 3Sandig V, Brand K, Herwigs S, et al. Adenovirally transferred p16INK/CDKN2 and p53 genes cooperate to induce apoptotic tumor cell death [J]. Nat Med, 1997, 3(3): 313-319.
  • 4Cheng JC, Matsen CB, Gonzales FA, et al. Inhibition of DNA methylation and reactivation of silenced genes by zebularine[ J]. J Natl Cancer Inst, 2003, 95(5): 399-409.
  • 5Yarbrough WG. The ARF-p16 gene locus in carcinogenesis and therapy of head and neck squamous cell carcinoma [ J ]. Laryngoscope, 2002, 112(12): 2114-2128.
  • 6Calbo J, Marotta M, Cascallo M, et al. Adenovirus-mediated wtp16 reintroduction induces cell cycle arrest or apoptosis in pancreatic cancer [J]. Cancer Gene Ther, 2001, 8(10): 740-750.
  • 7Hall M, Peters G. Genetic alterations of cyclins, cyclin-dependent kinase, and CDK inhibitors in human cancer [J]. Adv Cancer Res, 1996, 68: 67-108.
  • 8Lukas J, Aagaard L, Strauss M, et al. Oncogenic alterations of p16INK4/CDKN2 and cyclin D1 cooperate to deregulate G1 control [J]. Cancer Res, 1996, 55(21): 4818-4823.
  • 9苏长青,叶玉坤,汪栋,曹祥荣,李淑锋,单祥年.肺癌组织CDKN2/p16基因点突变的分析[J].中华医学遗传学杂志,2002,19(1):37-40. 被引量:4

二级参考文献11

  • 1Shapiro GI, Park JE, Edwards CD, et al. Multiple mechanisms of P16INK4A inactivation in non-small cell lung cancer cell lines. Cancer Res, 1995,55∶6200-6209.
  • 2Xiao S, Li D, Corson JM, et al. Codeletion of p15 and p16 genes in primary non-small cell lung carcinoma. Cancer Res, 1995,55∶2968-2971.
  • 3Castellano M, Pollock PM, Walters MK, et al. CDKN2A/p16 is inactivated in most melanoma cell lines. Cancer Res, 1997,57∶4868-4875.
  • 4Imai Y, Tsurutani N, Oda H, et al. p16INK4 gene mutations are relatively frequent in ampullary carcinomas. Jpn J Cancer Res, 1997,88∶941-946.
  • 5Muscarella P,Melvin WS, Fisher WE, et al. Genetic alterations in gastrinomas and nonfunctioning pancreatic neuroendocrine tumors: an analysis of p16/MTS1 tumor suppressor gene inactivation. Cancer Res, 1998,58∶237-240.
  • 6Kinoshita I, Dosaka-Akita H, Mishina T, et al. Altered p16INK4 and retinoblastoma protein status in non-small cell lung cancer:potential synergistic effect with altered p53 protein on proliferative activity. Cancer Res, 1996,56∶5557-5562.
  • 7Nakagawa K, Conrad NK, Williams JP, et al. Mechanism of inactivation of CDKN2 and MTS2 in non-small cell lung cancer and association with advanced stage. Oncogene, 1995,11∶1843-1851.
  • 8Washimi O, Nagatake M, Osada H, et al. In vivo occurrence of p16(MTS1) and p15(MTS2) alterations preferentially in non-small cell lung cancers. Cancer Res , 1995,55∶514-517.
  • 9Okamoto A, Demetrick DJ, Spilare EA, et al.Mutations and altered expression of p16 in human cancer. Proc Natl Acad Sci U S A, 1994,91∶11045-11055.
  • 10Hayashi N, Sugimoto Y, Tsuchiya E, et al. Somatic mutations of the MTS(multiple tumor suppressor) 1/CDK4I(cyclin-dependent kinase-4 inhibitor) gene in human primary non-small cell lung carcinoma. Biochem Biophys Res Commun, 1994,202∶1426-1435.

共引文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部